{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T05:33:34Z","timestamp":1791956014317,"version":"4.3.4"},"reference-count":73,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:p>Menopausal hormone therapy (HT) is highly effective against vasomotor symptoms (VMS). When HT is contraindicated, ineffective, or unacceptable, alternatives have included antidepressants, antiseizure, and antihypertensive formulations. Novel pharmacologic treatments for VMS have emerged in recent decades, some of which are already approved by the U.S. Food and Drug Administration (FDA) (eg, fezolinetant, a neurokinin 3B antagonist), and others are poised to seek FDA approval (eg, elinzanetant, a dual neurokinin 1B and 3B antagonist, and estetrol, a natural estradiol derivative that is unique to the pregnant state). Oxybutynin was shown to be effective for VMS and could provide additional benefits against overactive bladder, but long-term safety data are needed before wider utilization can be recommended.<\/jats:p>","DOI":"10.1097\/aog.0000000000006025","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T21:06:21Z","timestamp":1754600781000},"page":"473-486","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Novel Pharmacotherapies for Menopausal Symptoms"],"prefix":"10.1097","volume":"146","author":[{"given":"Caiyun","family":"Liao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubna","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"key":"R1-20260825","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"R2-20260825","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1210\/endo-128-5-2239","article-title":"Hypertrophy and increased gene expression of neurons containing neurokinin-B and substance-P messenger ribonucleic acids in the hypothalami of postmenopausal women","volume":"128","author":"Rance","year":"1991","journal-title":"Endocrinology"},{"key":"R3-20260825","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1210\/jc.2007-0553","article-title":"Hypertrophy and increased kisspeptin gene expression in the hypothalamic infundibular nucleus of postmenopausal women and ovariectomized monkeys","volume":"92","author":"Rometo","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"R4-20260825","doi-asserted-by":"crossref","first-page":"e13094","DOI":"10.1111\/jne.13094","article-title":"Neuroendocrine control of gonadotropin-releasing hormone: pulsatile and surge modes of secretion","volume":"34","author":"Goodman","year":"2022","journal-title":"J Neuroendocrinol"},{"key":"R5-20260825","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1210\/en.2010-0022","article-title":"Minireview: kisspeptin\/neurokinin B\/dynorphin (KNDy) cells of the arcuate nucleus: a central node in the control of gonadotropin-releasing hormone secretion","volume":"151","author":"Lehman","year":"2010","journal-title":"Endocrinology"},{"key":"R6-20260825","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.celrep.2018.06.037","article-title":"A neural circuit underlying the generation of hot flushes","volume":"24","author":"Padilla","year":"2018","journal-title":"Cell Rep"},{"key":"R7-20260825","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S0140-6736(23)00085-5","article-title":"Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study","volume":"401","author":"Lederman","year":"2023","journal-title":"Lancet"},{"key":"R8-20260825","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1210\/clinem\/dgad058","article-title":"Efficacy and safety of fezolinetant in moderate to severe vasomotor symptoms associated with menopause: a phase 3 RCT","volume":"108","author":"Johnson","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"R9-20260825","doi-asserted-by":"crossref","first-page":"5893","DOI":"10.1210\/jc.2019-00677","article-title":"Treatment of menopausal vasomotor symptoms with fezolinetant, a neurokinin 3 receptor antagonist: a phase 2a trial","volume":"104","author":"Depypere","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"R10-20260825","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/GME.0000000000001510","article-title":"A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause","volume":"27","author":"Fraser","year":"2020","journal-title":"Menopause"},{"key":"R11-20260825","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1111\/1471-0528.17773","article-title":"Fezolinetant impact on health\u2010related quality of life for vasomotor symptoms due to the menopause: pooled data from SKYLIGHT 1 and SKYLIGHT 2 randomised controlled trials","volume":"131","author":"Cano","year":"2024","journal-title":"BJOG"},{"key":"R12-20260825","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1097\/GME.0000000000001621","article-title":"Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA)","volume":"27","author":"Santoro","year":"2020","journal-title":"Menopause"},{"key":"R13-20260825","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/AOG.0000000000005114","article-title":"Safety of fezolinetant for vasomotor symptoms associated with menopause: a randomized controlled trial","volume":"141","author":"Neal-Perry","year":"2023","journal-title":"Obstet Gynecol"},{"key":"R14-20260825","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s12325-024-03073-8","article-title":"Safety of fezolinetant for treatment of moderate to severe vasomotor symptoms due to menopause: pooled analysis of three randomized phase 3 studies","volume":"42","author":"Kagan","year":"2025","journal-title":"Adv Ther"},{"key":"R22-20260825","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/GME.0000000000001500","article-title":"Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal women: a placebo-controlled, randomized trial","volume":"27","author":"Trower","year":"2020","journal-title":"Menopause"},{"key":"R23-20260825","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/GME.0000000000002138","article-title":"Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1)","volume":"30","author":"Simon","year":"2023","journal-title":"Menopause"},{"key":"R24-20260825","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1001\/jama.2024.14618","article-title":"Elinzanetant for the treatment of vasomotor symptoms associated with menopause: OASIS 1 and 2 randomized clinical trials","volume":"332","author":"Pinkerton","year":"2024","journal-title":"JAMA"},{"key":"R26-20260825","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2415566","article-title":"Elinzanetant for vasomotor symptoms from endocrine therapy for breast cancer","author":"Cardoso","year":"2025","journal-title":"N Engl J Med."},{"key":"R27-20260825","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0304-4165(65)90464-2","article-title":"15\u03b1-Hydroxylation: a new pathway of estrogen metabolism in the human fetus and newborn","volume":"100","author":"Schwers","year":"1965","journal-title":"Biochim Biophys Acta"},{"key":"R28-20260825","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jsbmb.2008.03.027","article-title":"Estetrol: a unique steroid in human pregnancy","volume":"110","author":"Holinka","year":"2008","journal-title":"J Steroid Biochem Mol Biol"},{"key":"R29-20260825","first-page":"413","article-title":"Isolation of 15\u03b1-hydroxy-oestriol from pregnancy urine and from the urine of newborn infants","volume":"56","author":"Zucconi","year":"1967","journal-title":"Acta Endocrinol"},{"key":"R30-20260825","first-page":"597","article-title":"Metabolism of oestrone sulphate by the previable human foetus","volume":"50","author":"Schwers","year":"1965","journal-title":"Acta Endocrinol"},{"key":"R31-20260825","first-page":"208","article-title":"Studies on the metabolism of C-19 steroids in the human foeto-placental unit: 4: aromatisation and hydroxylation products formed by previable foetuses perfused with androstenedione and, testosterone","volume":"57","author":"Mancuso","year":"1968","journal-title":"Acta Endocrinol"},{"key":"R32-20260825","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1095\/biolreprod22.4.913","article-title":"Comparison of effects of estertrol and tamoxifen with those of estriol and estradiol on the immature rat uterus","volume":"22","author":"Holinka","year":"1980","journal-title":"Biol Reprod"},{"key":"R33-20260825","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.15252\/emmm.201404112","article-title":"The uterine and vascular actions of estetrol delineate a distinctive profile of estrogen receptor \u03b1 modulation, uncoupling nuclear and membrane activation","volume":"6","author":"Abot","year":"2014","journal-title":"EMBO Mol Med"},{"issue":"suppl 1","key":"R34-20260825","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/13697130701842490","article-title":"Estrogenic uterovaginal effects of oral estetrol in the modified Allen\u2013Doisy test","volume":"11","author":"Heegaard","year":"2008","journal-title":"Climacteric"},{"key":"R35-20260825","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.thromres.2022.09.007","article-title":"Estetrol is not a SERM but a NEST and has a specific safety profile on coagulation","volume":"232","author":"Douxfils","year":"2023","journal-title":"Thromb Res"},{"key":"R36-20260825","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/17512433.2022.2054413","article-title":"Profile of estetrol, a promising native estrogen for oral contraception and the relief of climacteric symptoms of menopause","volume":"15","author":"G\u00e9rard","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R37-20260825","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.steroids.2015.01.003","article-title":"Effect of estetrol on beta-endorphin level in female rats","volume":"95","author":"Pluchino","year":"2015","journal-title":"Steroids"},{"key":"R38-20260825","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1097\/GME.0000000000001561","article-title":"A multicenter, randomized study to select the minimum effective dose of estetrol (E4) in postmenopausal women (E4Relief): part 1: vasomotor symptoms and overall safety","volume":"27","author":"Gaspard","year":"2020","journal-title":"Menopause"},{"key":"R39-20260825","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/GME.0000000000002167","article-title":"A multicenter, randomized, placebo-controlled study to select the minimum effective dose of estetrol in postmenopausal participants (E4Relief): part 2\u2014vaginal cytology, genitourinary syndrome of menopause, and health-related quality of life","volume":"30","author":"Gaspard","year":"2023","journal-title":"Menopause"},{"key":"R40-20260825","first-page":"399","article-title":"Estetrol, a fetal steroid for the treatment of adults","volume":"12","author":"Hjt","year":"2016","journal-title":"J Reprod Med Endocrinol"},{"key":"R42-20260825","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.maturitas.2016.06.017","article-title":"Clinical effects of the fetal estrogen estetrol in a multiple-rising-dose study in postmenopausal women","volume":"91","author":"Coelingh Bennink","year":"2016","journal-title":"Maturitas"},{"key":"R43-20260825","doi-asserted-by":"crossref","first-page":"580","DOI":"10.3390\/biom14050580","article-title":"Estetrol inhibits endometriosis development in an in vivo murine model","volume":"14","author":"Zabala","year":"2024","journal-title":"Biomolecules"},{"key":"R44-20260825","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.3390\/biomedicines11041169","article-title":"Estetrol increases progesterone genetic response without triggering common estrogenic effects in endometriotic cell lines and primary cultures","volume":"11","author":"Pati\u00f1o-Garc\u00eda","year":"2023","journal-title":"Biomedicines"},{"key":"R46-20260825","first-page":"40","article-title":"GnRH agonists in the treatment of symptomatic endometriosis: a review","volume":"4","author":"Surrey","year":"2023","journal-title":"F S Rep"},{"key":"R47-20260825","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/humrep\/dead263","article-title":"Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study","volume":"39","author":"Becker","year":"2024","journal-title":"Hum Reprod"},{"key":"R48-20260825","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3109\/13625187.2015.1068934","article-title":"Unique effects on hepatic function, lipid metabolism, bone and growth endocrine parameters of estetrol in combined oral contraceptives","volume":"20","author":"Mawet","year":"2015","journal-title":"Eur J Contraception Reprod Health Care"},{"issue":"suppl 1","key":"R49-20260825","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/13697130701798692","article-title":"Oral bioavailability and bone-sparing effects of estetrol in an osteoporosis model","volume":"11","author":"Coelingh Bennink","year":"2008","journal-title":"Climacteric"},{"key":"R50-20260825","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10911-021-09497-0","article-title":"Estetrol and mammary gland: friends or foes?","volume":"26","author":"Gallez","year":"2021","journal-title":"J Mammary Gland Biol Neoplasia"},{"key":"R51-20260825","doi-asserted-by":"crossref","first-page":"17621","DOI":"10.18632\/oncotarget.4184","article-title":"Combined estrogenic and anti-estrogenic properties of estetrol on breast cancer may provide a safe therapeutic window for the treatment of menopausal symptoms","volume":"6","author":"G\u00e9rard","year":"2015","journal-title":"Oncotarget"},{"key":"R52-20260825","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3389\/fendo.2014.00080","article-title":"Effects of estetrol on migration and invasion in T47-D breast cancer cells through the actin cytoskeleton","volume":"5","author":"Giretti","year":"2014","journal-title":"Front Endocrinol"},{"key":"R53-20260825","doi-asserted-by":"crossref","first-page":"1178223419844198","DOI":"10.1177\/1178223419844198","article-title":"Pro-apoptotic effects of estetrol on long-term estrogen-deprived breast cancer cells and at low doses on hormone-sensitive cells","volume":"13","author":"Yue","year":"2019","journal-title":"Breast Cancer Basic Clin Res"},{"key":"R54-20260825","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1530\/JOE-14-0549","article-title":"Estetrol is a weak estrogen antagonizing estradiol-dependent mammary gland proliferation","volume":"224","author":"G\u00e9rard","year":"2015","journal-title":"J Endocrinol"},{"key":"R55-20260825","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.3390\/cancers13102486","article-title":"Estetrol combined to progestogen for menopause or contraception indication is neutral on breast cancer","volume":"13","author":"Gallez","year":"2021","journal-title":"Cancers"},{"key":"R56-20260825","first-page":"95","article-title":"Estetrol prevents and suppresses mammary tumors induced by DMBA in a rat model","volume":"9","author":"Visser","year":"2012","journal-title":"Horm Mol Biol Clin Invest"},{"key":"R57-20260825","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1093\/carcin\/bgu144","article-title":"Antiestrogenic effects of the fetal estrogen estetrol in women with estrogen-receptor positive early breast cancer","volume":"35","author":"Singer","year":"2014","journal-title":"Carcinogenesis"},{"issue":"suppl 1","key":"R58-20260825","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/13697130701851814","article-title":"Estetrol does not bind sex hormone binding globulin or increase its production by human HepG2 cells","volume":"11","author":"Hammond","year":"2008","journal-title":"Climacteric"},{"key":"R59-20260825","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0378-5122(90)90003-O","article-title":"Pharmacokinetics of oestrogens and progestogens","volume":"12","author":"Kuhl","year":"1990","journal-title":"Maturitas"},{"issue":"suppl 1","key":"R60-20260825","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/13697130802056511","article-title":"First human exposure to exogenous single-dose oral estetrol in early postmenopausal women","volume":"11","author":"Visser","year":"2008","journal-title":"Climacteric"},{"issue":"suppl 1","key":"R61-20260825","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1080\/13697130802050340","article-title":"In vitro effects of estetrol on receptor binding, drug targets and human liver cell metabolism","volume":"11","author":"Visser","year":"2008","journal-title":"Climacteric"},{"key":"R62-20260825","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/GME.0000000000002028","article-title":"The 2022 hormone therapy position statement of the North American Menopause Society","volume":"29","author":"Faubion","year":"2022","journal-title":"Menopause"},{"key":"R63-20260825","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/cpt.1007","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and tamoxifen therapy","volume":"103","author":"Goetz","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"R64-20260825","first-page":"3","article-title":"Estetrol as estrogen in a combined oral contraceptive, from the first in-human study to the contraceptive efficacy","volume":"3","author":"Mawet","year":"2021","journal-title":"Eur Gynecol Obstet"},{"key":"R65-20260825","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.contraception.2016.08.018","article-title":"Reduced hemostatic effects with drospirenone-based oral contraceptives containing estetrol vs. ethinyl estradiol","volume":"95","author":"Kluft","year":"2017","journal-title":"Contraception"},{"key":"R66-20260825","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.contraception.2021.01.001","article-title":"Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone","volume":"103","author":"Klipping","year":"2021","journal-title":"Contraception"},{"key":"R67-20260825","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/13697137.2022.2139599","article-title":"Impact of estetrol (E4) on hemostasis, metabolism and bone turnover in postmenopausal women","volume":"26","author":"Douxfils","year":"2023","journal-title":"Climacteric"},{"key":"R68-20260825","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.mce.2018.06.010","article-title":"Effect of estetrol, a selective nuclear estrogen receptor modulator, in mouse models of arterial and venous thrombosis","volume":"477","author":"Val\u00e9ra","year":"2018","journal-title":"Mol Cell Endocrinol"},{"key":"R69-20260825","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/13697137.2023.2292066","article-title":"Low thrombin generation in postmenopausal women using estetrol","volume":"27","author":"Morimont","year":"2024","journal-title":"Climacteric"},{"key":"R70-20260825","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.contraception.2007.11.014","article-title":"Ovulation inhibition by estetrol in an in vivo model","volume":"77","author":"Coelingh Bennink","year":"2008","journal-title":"Contraception"},{"key":"R72-20260825","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/GME.0000000000002537","article-title":"The rediscovery of estetrol and its implications for estrogen treatment","volume":"32","author":"Coelingh Bennink","year":"2025","journal-title":"Menopause"},{"key":"R73-20260825","first-page":"1158","article-title":"The effect of estrogen replacement therapy on plasma serotonin and catecholamines of postmenopausal women","volume":"32","author":"Blum","year":"1996","journal-title":"Isr J Med Sci"},{"key":"R74-20260825","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/gme.0b013e3181f7a17a","article-title":"Mechanisms of cutaneous vasodilation during the postmenopausal hot flash","volume":"18","author":"Low","year":"2011","journal-title":"Menopause"},{"key":"R75-20260825","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.jvs.2011.12.039","article-title":"A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis","volume":"55","author":"Wolosker","year":"2012","journal-title":"J Vasc Surg"},{"key":"R76-20260825","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/01.gme.0000243574.01441.3e","article-title":"Oxybutynin for refractory hot flashes in cancer patients","volume":"14","author":"Sexton","year":"2007","journal-title":"Menopause"},{"key":"R77-20260825","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1097\/GME.0000000000000773","article-title":"Extended-release oxybutynin therapy for vasomotor symptoms in women: a randomized clinical trial","volume":"23","author":"Simon","year":"2016","journal-title":"Menopause"},{"key":"R78-20260825","doi-asserted-by":"crossref","first-page":"pkz088","DOI":"10.1093\/jncics\/pkz088","article-title":"Oxybutynin vs placebo for hot flashes in women with or without breast cancer: a randomized, double-blind clinical trial (ACCRU SC-1603)","volume":"4","author":"Leon-Ferre","year":"2020","journal-title":"JNCI Cancer Spectr"},{"key":"R79-20260825","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s40261-021-01020-x","article-title":"Overactive bladder prescribing considerations: the role of polypharmacy, anticholinergic burden, and CYP2D6 drug\u2012drug interactions","volume":"41","author":"Rutman","year":"2021","journal-title":"Clin Drug Invest"},{"key":"R80-20260825","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.2147\/CIA.S252852","article-title":"Cognitive effects of anticholinergic load in women with overactive bladder","volume":"15","author":"Araklitis","year":"2020","journal-title":"Clin Intervent Aging"},{"key":"R81-20260825","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s11934-011-0198-9","article-title":"Antimuscarinic drugs: review of the cognitive impact when used to treat overactive bladder in elderly patients","volume":"12","author":"Pagoria","year":"2011","journal-title":"Curr Urol Rep"},{"key":"R82-20260825","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1111\/j.1742-1241.2008.01849.x","article-title":"Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin","volume":"62","author":"Kay","year":"2008","journal-title":"Int J Clin Pract"},{"key":"R83-20260825","first-page":"639","article-title":"A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs","volume":"29","author":"Tannenbaum","year":"2012","journal-title":"Drugs Aging"},{"key":"R84-20260825","doi-asserted-by":"crossref","first-page":"e0175335","DOI":"10.1371\/journal.pone.0175335","article-title":"Association between different anticholinergic drugs and subsequent dementia risk in patients with diabetes mellitus","volume":"12","author":"Yang","year":"2017","journal-title":"PLoS One"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000006025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T10:00:21Z","timestamp":1787652021000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000006025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":73,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000006025","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,7]]},"assertion":[{"value":"2025-03-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}